Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Xu-Monette Z, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodriguez-Perales S, Torres-Ruiz R, Manyam G, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkaer K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Feb 11. pii: canimm.0439.2018. doi: 10.1158/2326-6066.CIR-18-0439. [Epub ahead of print]

PMID:
30745366
2.

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.

González-Rincón J, Gómez S, Martinez N, Troulé K, Perales-Patón J, Derdak S, Beltrán S, Fernández-Cuevas B, Pérez-Sanz N, Nova-Gurumeta S, Gut I, Al-Shahrour F, Piris MA, García-Marco JA, Sánchez-Beato M.

Sci Rep. 2019 Jan 30;9(1):975. doi: 10.1038/s41598-018-37389-7.

3.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jan 21. doi: 10.1038/s41379-018-0193-5. [Epub ahead of print]

PMID:
30666052
4.

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ.

Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10. Review.

5.

Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.

Xochelli A, Bikos V, Polychronidou E, Galigalidou C, Agathangelidis A, Charlotte F, Moschonas P, Davis Z, Colombo M, Roumelioti M, Sutton LA, Groenen P, van den Brand M, Boudjoghra M, Algara P, Traverse-Glehen A, Ferrer A, Stalika E, Karypidou M, Kanellis G, Kalpadakis C, Mollejo M, Pangalis G, Vlamos P, Amini RM, Pospisilova S, Gonzalez D, Ponzoni M, Anagnostopoulos A, Giudicelli V, Lefranc MP, Espinet B, Panagiotidis P, Piris MA, Du MQ, Rosenquist R, Papadaki T, Belessi C, Ferrarini M, Oscier D, Tzovaras D, Ghia P, Davi F, Hadzidimitriou A, Stamatopoulos K.

J Pathol. 2018 Nov 28. doi: 10.1002/path.5209. [Epub ahead of print]

PMID:
30484876
6.

The Spectrum of EBV-Positive Mucocutaneous Ulcer: A Study of 9 Cases.

Prieto-Torres L, Eraña I, Gil-Redondo R, Gómez de la Riva I, Manso R, Pajares R, Córdoba R, Machan S, Ara M, Requena L, Piris MÁ, Rodríguez-Pinilla SM.

Am J Surg Pathol. 2019 Feb;43(2):201-210. doi: 10.1097/PAS.0000000000001186.

PMID:
30418184
7.

DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers.

Onaindia A, González de Villambrosía S, Prieto-Torres L, Rodríguez-Pinilla SM, Montes-Moreno S, González-Vela C, Piris MA.

Haematologica. 2018 Oct 25. pii: haematol.2018.205880. doi: 10.3324/haematol.2018.205880. [Epub ahead of print]

8.

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR.

Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP.

Oncotarget. 2018 Jul 20;9(56):30869-30882. doi: 10.18632/oncotarget.25766. eCollection 2018 Jul 20.

9.

Atypical Histiocytic Lesion Preceding a Peripheral T-Cell Lymphoma Involving the Skin Exhibiting the Same Molecular Alterations.

Machan S, Córdoba R, Carvajal N, Requena L, Piris MÁ, Facchetti F, Rodríguez-Pinilla SM.

Am J Dermatopathol. 2019 Feb;41(2):148-154. doi: 10.1097/DAD.0000000000001245.

PMID:
30085957
10.

Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis: Analysis of Histology and Lymphoid Subpopulations.

Siliézar MM, Muñoz CC, Solano-Iturri JD, Ortega-Comunian L, Mollejo M, Montes-Moreno S, Piris MA.

Am J Clin Pathol. 2018 Aug 30;150(4):310-317. doi: 10.1093/ajcp/aqy056.

PMID:
30007337
11.

Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications.

Infante MS, Piris MÁ, Hernández-Rivas JÁ.

Med Clin (Barc). 2018 Nov 9;151(9):362-367. doi: 10.1016/j.medcli.2018.05.002. Epub 2018 Jun 9. Review. English, Spanish.

PMID:
29895422
12.

Mycosis fungoides progression could be regulated by microRNAs.

Manso R, Martínez-Magunacelaya N, Eraña-Tomás I, Monsalvez V, Rodríguez-Peralto JL, Ortiz-Romero PL, Santonja C, Cristóbal I, Piris MA, Rodríguez-Pinilla SM.

PLoS One. 2018 Jun 12;13(6):e0198477. doi: 10.1371/journal.pone.0198477. eCollection 2018.

13.

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.

Pérez-Salvia M, Aldaba E, Vara Y, Fabre M, Ferrer C, Masdeu C, Zubia A, Sebastian ES, Otaegui D, Llinàs-Arias P, Rosselló-Tortella M, Berdasco M, Moutinho C, Setien F, Villanueva A, González-Barca E, Muncunill J, Navarro JT, Piris MA, Cossio FP, Esteller M.

Haematologica. 2018 Nov;103(11):e537-e540. doi: 10.3324/haematol.2018.189241. Epub 2018 Jun 7. No abstract available.

14.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

15.

Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.

Manso R, González-Rincón J, Rodríguez-Justo M, Roncador G, Gómez S, Sánchez-Beato M, Piris MA, Rodríguez-Pinilla SM.

Oncotarget. 2018 Mar 1;9(22):16124-16133. doi: 10.18632/oncotarget.24592. eCollection 2018 Mar 23.

16.

Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.

Suárez-González J, Martínez-Laperche C, Martínez N, Rodríguez-Macías G, Kwon M, Balsalobre P, Carbonell D, Chicano M, Serrano D, Triviño JC, Piris MÁ, Gayoso J, Díez-Martín JL, Buño I.

Leukemia. 2018 Aug;32(8):1822-1826. doi: 10.1038/s41375-018-0042-z. Epub 2018 Feb 5. No abstract available.

PMID:
29568094
17.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
18.

Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Mata E, Díaz-López A, Martín-Moreno AM, Sánchez-Beato M, Varela I, Mestre MJ, Santonja C, Burgos F, Menárguez J, Estévez M, Provencio M, Sánchez-Espiridión B, Díaz E, Montalbán C, Piris MA, García JF.

Oncotarget. 2017 Nov 30;8(67):111386-111395. doi: 10.18632/oncotarget.22799. eCollection 2017 Dec 19.

19.

Re-Defining 'Reactive' lymphadenopathies: How molecular lessons have changed our minds.

Gru AA, Piris MA.

Semin Diagn Pathol. 2018 Jan;35(1):1-3. doi: 10.1053/j.semdp.2017.12.002. Epub 2017 Dec 6. No abstract available.

PMID:
29273279
20.

Mutational profile of primary breast diffuse large B-cell lymphoma.

Franco F, González-Rincón J, Lavernia J, García JF, Martín P, Bellas C, Piris MA, Pedrosa L, Miramón J, Gómez-Codina J, Rodríguez-Abreu D, Machado I, Illueca C, Alfaro J, Provencio M, Sánchez-Beato M.

Oncotarget. 2017 Oct 24;8(61):102888-102897. doi: 10.18632/oncotarget.21986. eCollection 2017 Nov 28.

21.

Castleman Disease and Rosai-Dorfman Disease.

Piris MA, Aguirregoicoa E, Montes-Moreno S, Celeiro-Muñoz C.

Semin Diagn Pathol. 2018 Jan;35(1):44-53. doi: 10.1053/j.semdp.2017.11.014. Epub 2017 Dec 2. Review.

PMID:
29217303
22.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
23.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M, García-Cosio M, Menárguez J, Piris MA, Rodríguez-Pinilla SM.

Br J Haematol. 2018 Nov;183(3):497-501. doi: 10.1111/bjh.14984. Epub 2017 Oct 26. No abstract available.

PMID:
29076126
24.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

25.

B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report.

Sabatino R, Aquino G, Pinto A, Piris MA, Marra L, Napolitano M, De Chiara A, Franco R.

Hematol Oncol. 2017 Sep;35(3):380-384. doi: 10.1002/hon.2269. Epub 2015 Nov 2. No abstract available.

PMID:
28933515
26.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

27.

Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma.

Manso R, Martínez-Magunacelaya N, Chamizo C, Rojo F, Piris MÁ, Rodriguez-Pinilla SM.

Br J Haematol. 2018 Aug;182(4):587-590. doi: 10.1111/bjh.14824. Epub 2017 Jul 12. No abstract available.

PMID:
28699695
28.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

29.

Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.

Campos-Martín Y, Martínez N, Martínez-López A, Cereceda L, Casado F, Algara P, Oscier D, Menarguez FJ, García JF, Piris MA, Mollejo M.

Haematologica. 2017 Aug;102(8):e310-e312. doi: 10.3324/haematol.2016.161711. Epub 2017 May 18. No abstract available.

30.

Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines.

Mondejar R, Pérez C, Onaindia A, Martinez N, González-Rincón J, Pisonero H, Vaqué JP, Cereceda L, Santibañez M, Sánchez-Beato M, Piris MA.

PLoS One. 2017 May 15;12(5):e0177524. doi: 10.1371/journal.pone.0177524. eCollection 2017.

31.

Splenic marginal zone lymphoma.

Piris MA, Onaindía A, Mollejo M.

Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):56-64. doi: 10.1016/j.beha.2016.09.005. Epub 2016 Nov 5. Review.

PMID:
28288718
32.

Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations.

Curiel-Olmo S, Mondéjar R, Almaraz C, Mollejo M, Cereceda L, Marès R, Derdak S, Campos-Martín Y, Batlle A, González de Villambrosía S, Gut M, Blanc J, Traverse-Glehen A, Verney A, Baseggio L, Camacho FI, Wotherspoon A, Stamatopoulos K, Xochelli A, Papadaki T, Kanellis G, Ponzoni M, García-Cosío M, Vaqué JP, Beltrán S, Gut I, Piris MA, Martínez N.

Blood. 2017 Feb 23;129(8):1042-1045. doi: 10.1182/blood-2016-11-751024. Epub 2017 Jan 9. No abstract available.

33.

Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, Quinn SA, Kim MY, Laginestra MA, Kim C, Fiore D, Bhagat G, Piris MA, Campo E, Lossos IS, Bernard OA, Inghirami G, Pileri S, Bustelo XR, Rabadan R, Ferrando AA, Palomero T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114. Epub 2017 Jan 6.

34.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

35.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

36.

Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas.

González-Vela MDC, Curiel-Olmo S, Derdak S, Beltran S, Santibañez M, Martínez N, Castillo-Trujillo A, Gut M, Sánchez-Pacheco R, Almaraz C, Cereceda L, Llombart B, Agraz-Doblas A, Revert-Arce J, López Guerrero JA, Mollejo M, Marrón PI, Ortiz-Romero P, Fernandez-Cuesta L, Varela I, Gut I, Cerroni L, Piris MÁ, Vaqué JP.

J Invest Dermatol. 2017 Jan;137(1):197-206. doi: 10.1016/j.jid.2016.08.015. Epub 2016 Sep 1.

37.

Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.

Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, Villambrosía SG, Linares E, Ranchal T, Rodriguez-Pinilla M, Batlle A, Cereceda-Company L, Revert-Arce JB, Almaraz C, Piris MA.

Mod Pathol. 2017 Jan;30(1):85-94. doi: 10.1038/modpathol.2016.162. Epub 2016 Sep 30.

38.

Nodal marginal zone mutational signature.

Piris MA.

Blood. 2016 Sep 8;128(10):1315-6. doi: 10.1182/blood-2016-07-724963. No abstract available.

39.

Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression.

Suárez AE, Artiga MJ, Santonja C, Montes-Moreno S, De Pablo P, Requena L, Piris MA, Rodríguez-Pinilla SM.

J Cutan Pathol. 2016 Dec;43(12):1203-1210. doi: 10.1111/cup.12814. Epub 2016 Oct 4.

PMID:
27596815
40.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

41.

C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.

Manso R, Bellas C, Martín-Acosta P, Mollejo M, Menárguez J, Rojo F, Llamas P, Piris MA, Rodríguez-Pinilla SM.

Haematologica. 2016 Aug;101(8):e336-8. doi: 10.3324/haematol.2016.143768. Epub 2016 May 5. No abstract available.

42.

Erratum: Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.

Curiel-Olmo S, García-Castaño A, Vidal R, Pisonero H, Varela I, León-Castillo A, Trillo E, González-Vela C, García-Diaz N, Almaraz C, Moreno T, Cereceda L, Madureira R, Martinez N, Ortiz-Romero P, Valdizán E, Piris MA, Vaqué JP.

Oncotarget. 2016 Feb 2;7(5):6352. doi: 10.18632/oncotarget.7118. No abstract available.

43.

Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance.

Bermudez G, González de Villambrosía S, Martínez-López A, Batlle A, Revert-Arce JB, Cereceda Company L, Ortega Bezanilla C, Piris MA, Montes-Moreno S.

Am J Surg Pathol. 2016 Jul;40(7):943-9. doi: 10.1097/PAS.0000000000000628.

PMID:
26945339
44.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.

Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296. Epub 2016 Feb 29.

45.

p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients.

Manso R, Roncador G, Montes-Moreno S, Rojo F, Pérez-Sáenz MÁ, Mollejo M, Menárguez J, Carvajal N, García-Cosio M, Llamas P, Piris MA, Rodríguez-Pinilla SM.

Br J Haematol. 2017 Feb;176(4):661-664. doi: 10.1111/bjh.13972. Epub 2016 Feb 25. No abstract available.

PMID:
26915336
46.

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.

Batlle-López A, González de Villambrosía S, Francisco M, Malatxeberria S, Sáez A, Montalban C, Sánchez L, Garcia J, González-Barca E, López-Hernández A, Ruiz-Marcellan MC, Mollejo M, Grande C, Richards KL, Hsi ED, Tzankov A, Visco C, Xu-Monette ZY, Cao X, Young KH, Piris MÁ, Conde E, Montes-Moreno S.

Oncotarget. 2016 Apr 5;7(14):18036-49. doi: 10.18632/oncotarget.7495.

47.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.

Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.

Aging (Albany NY). 2016 Feb;8(2):345-65.

48.

Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.

Battle-Lopez A, Gonzalez de Villambrosia S, Nuñez J, Cagigal ML, Montes-Moreno S, Conde E, Piris MA.

Expert Rev Anticancer Ther. 2016;16(4):411-21. doi: 10.1586/14737140.2016.1149065. Epub 2016 Mar 7. Review.

PMID:
26838128
49.

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.

Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton LA, Papadopoulos G, Agathangelidis A, Papadopoulou E, Davis Z, Algara P, Kanellis G, Traverse-Glehen A, Mollejo M, Anagnostopoulos A, Ponzoni M, Gonzalez D, Pospisilova S, Matutes E, Piris MA, Papadaki T, Ghia P, Rosenquist R, Oscier D, Darzentas N, Tzovaras D, Belessi C, Hadzidimitriou A, Stamatopoulos K.

Clin Cancer Res. 2016 Apr 15;22(8):2032-40. doi: 10.1158/1078-0432.CCR-15-1170. Epub 2015 Dec 8.

50.

CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.

Onaindia A, Martínez N, Montes-Moreno S, Almaraz C, Rodríguez-Pinilla SM, Cereceda L, Revert JB, Ortega C, Tardio A, González L, García S, Camacho FI, González-Vela C, Piris MA.

Am J Surg Pathol. 2016 Mar;40(3):378-85. doi: 10.1097/PAS.0000000000000571.

PMID:
26574847

Supplemental Content

Loading ...
Support Center